

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA114 Methadone and buprenorphine for the management of opioid dependence

This guidance was issued January 2007 with a review date of March 2010

Background

At the GE meeting 29 June 2010 and 17 August 2010 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	A review of the guidance should be transferred to the 'static guidance' list. That we consult on this proposal.
------------------------------------	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	A review of the guidance should be transferred to the 'static guidance' list
--	--

Respondent	Response to proposal	Details	Comment from Technology Appraisal
British Association for Psychopharmacology	No comment		Comment noted. No action required.
Medicines and Healthcare products Regulatory Agency	No comment		Comment noted. No action required.
NHS Quality Improvement Scotland	No comment		Comment noted. No action required.
National Treatment Agency for Substance Misuse (NTA)	Agree	<p>“The NTA has commissioned.....a review of current prescribing practice in the treatment of opioid dependence in England. Led by Professor John Strang (Director of the National Addiction Centre), this review will consider current evidence and seek to build professional consensus about ways to ensure that long-term methadone maintenance does not become the norm by default for the majority of opioid dependent drug treatment clients. This review is concerned with improving practice and the application of the technology and is not expected to cut across the current recommendations in technology appraisal No 114.</p> <p>The current drug strategy review and the Strang review, which is a potentially authoritative piece of work, may have implications for NICE guidance. Therefore,</p>	<p>Comments noted.</p> <p>Please note that an appraisal on the static list can still be reviewed if substantial new evidence comes to light which</p>

		the NTA view is that it might be more sensible for NICE to postpone the decision to put Technology Appraisal Guidance No 114 on the static list until the Strang review has reported and the new drug strategy priorities are clear.”	may materially affect the recommendations contained within it.
Public Health Wales NHS Trust	Agree		Comment noted. No action required.
Royal College of Nursing	No objection	We have been informed of the new guidelines on drugs maintenance treatment and time limited treatment, which the government has asked Professor Strang to develop. There is currently a consultation by the Home Office on Drug Strategy which includes a recovery/abstinence agenda. In our view, this approach is not in the patients’ interest. The consultation is available via the following link: http://www.homeoffice.gov.uk/publications/consultations/cons-drug-strategy-2010 . We are aware that since the publication of the NICE guidelines and DOH guidelines in 2007, no new evidence has made material effect on these guidelines. We are however, concerned that political changes may be attempting to alter things and would strongly object to the negative impact this could have on service provision.	Comments noted. Please note that an appraisal on the static list can still be reviewed if substantial new evidence comes to light which may materially affect the recommendations contained within it.

No response received from:

Consultees	Commentators (no right to submit or appeal)
<p>Manufacturers/sponsors</p> <ul style="list-style-type: none"> • AAH Pharmaceuticals (methadone) • Actavis UK (buprenorphine, methadone) • Arrow Generics (buprenorphine) • Auden McKenzie (methadone) • M & A Pharmachem (methadone) • Martindale Pharma (methadone) • Morningside Healthcare (buprenorphine) • Pinewood Healthcare (methadone) • Rosemont Pharmaceuticals (methadone) • SNS Pharmaceuticals (methadone) • Schering-Plough Ltd (buprenorphine) • Teva UK (buprenorphine) • Thornton & Ross (methadone) • Wockhardt UK (methadone) <p>Patient/carer groups</p> <ul style="list-style-type: none"> • Addaction • Adfam • Alliance • Afiya Trust • Black Health Agency • Chinese National Healthy Living Centre 	<p>General</p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • HM Prison Service • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p>Comparator manufacturers</p> <ul style="list-style-type: none"> • None <p>Relevant research groups</p> <ul style="list-style-type: none"> • Action on Addiction • Centre for Research on Drugs and Health Behaviour (Imperial College) • Department of Addictive Behaviour and Psychological Medicine (St George's Hospital Medical School) • DrugScope

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Counsel and Care • Equalities National Council • Families Anonymous UK • Lifeline • Muslim Council of Britain • Muslim Health Network • Rehabilitation for Addicted Prisoners Trust (RAPt) • Release • South Asian Health Foundation • Specialised Healthcare Alliance • Turning Point <p>Professional groups</p> <ul style="list-style-type: none"> • Addiction Recovery Foundation • Association of Nurses in Substance Abuse • British Association for Services to the Elderly • British Geriatrics Society • European Association for the Treatment of Addiction UK • Federation of Drug and Alcohol Professionals • National Drug Prevention Alliance • National Pharmaceutical Association • Pharmaceutical Services Negotiating Committee • Royal College of General Practitioners • Royal College of Physicians • Royal College of Psychiatrists (Addictions Faculty) • Royal Pharmaceutical Society • Royal Society of Medicine 	<ul style="list-style-type: none"> • Independent Drug Monitoring Unit (IDMU) • MRC Clinical Trials Unit • National Addiction Centre (Institute of Psychiatry) • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • Society for the Study of Addiction <p>Assessment Group</p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research (NIHR) Health Technology Assessment Programme <p>Associated Guideline Groups</p> <ul style="list-style-type: none"> • National Collaborating Centre for Mental Health <p>Associated Public Health Groups</p> <ul style="list-style-type: none"> • none

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Specialist Clinical Addiction Network (SCAN) • Substance Misuse Management in General Practice (SMMGP) • United Kingdom Clinical Pharmacy Association • UK Harm Reduction Alliance <p>Others</p> <ul style="list-style-type: none"> • Department of Health • Kingston PCT • NHS Manchester • Welsh Assembly Government 	

GE paper sign-off: Elisabeth George, 05 10 10

Contributors to this paper:

Information Specialist: Daniel Tuvey
 Technical Lead: Whitney Miller
 Technical Adviser: Zoe Charles
 Project Manager: Andrew Harding